• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Cancer Drugs Fund (CDF) - Articles and news items

UPDATE: The Cancer Drugs Fund

Blog, Industry news / 1 March 2017 / Niamh Louise Marriott, Digital Editor

This page will be updated as the results from the Cancer Drugs Fund appraisal are announced by The National Institute of Health and Care Excellence (NICE).

NICE approves former CDF kidney cancer drug for NHS use

Industry news / 12 January 2017 / Niamh Marriott, Digital Editor

Everolimus (Afinitor, Novartis) is now recommended to be available on the NHS as a treatment option for some patients with advanced renal cell carcinoma…

NICE says Roche’s trastuzumab emtansine too expensive for routine NHS use

Industry news / 29 December 2016 / Niamh Louise Marriott, Digital Editor

Trastuzumab emtansine is currently being funded through the Cancer Drugs Fund (CDF). NICE is looking again at its 2015 guidance to see whether it should…

Price drop means leukaemia CDF drug will be routinely available

Industry news / 2 December 2016 / Niamh Louise Marriott, Digital Editor

Ibrutinib had only previously been available through the CDF. Following a reduction in its price for the NHS, it is now recommended in further guidance…

NICE approves three quarters of CDF drugs for routine NHS use

Industry news / 17 November 2016 / Niamh Louise Marriott, Digital Content Producer

More than 75% of treatments in the Cancer Drugs Fund (CDF) which have been reappraised by the National Institute for Health and Care Excellence (NICE) have received positive recommendations for routine use in the NHS. NICE has been reappraising cancer drugs which had not been recommended in previous NICE guidance (11 drug indications in total), […]

C is for Cancer Drugs Fund

Blog / 16 November 2016 / Niamh Louise Marriott, Digital Content Producer

C is for Cancer Drugs Fund – the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest on the Cancer Drugs Fund

NICE draft guidance recommends treatments for breast and lung cancer

Industry news / 10 November 2016 / Niamh Louise Marriott, Digital Content Producer

NICE recommends 2 cancer drugs for routine use on the NHS as part of its programme to appraise treatments that were available on the Cancer Drugs Fund…

Life-extending breast cancer drug approved by NICE

Industry news / 3 November 2016 / Niamh Louise Marriott, Digital Content Producer

NICE has said eribulin, which is also called Halaven and made by Eisai, should be an option for people with locally advanced or metastatic breast cancer…

NICE says CDF case for nivolumab to treat lung cancer is not clear cut

Industry news / 14 October 2016 / Niamh Louise Marriott, Digital Content Producer

NICE’s appraisal committee concluded that nivolumab was not cost-effective for all patients in the treatment of non small-cell lung cancer…

NICE recommends first drug for the Cancer Drugs Fund

Industry news / 4 October 2016 / Niamh Louise Marriott, Digital Content Producer

Osimertinib is the first new cancer drug to be introduced into the NHS under a Cancer Drugs Fund managed access agreement…

Re-evaluating the Cancer Drugs Fund: Out with the old, in with the new

Blog, Z Homepage promo / 31 August 2016 / Niamh Louise Marriott, Digital Content Producer

In April of this year, NICE started to assess the cost and clinical effectiveness of every drug currently in the old cancer drugs fund…